Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 66
- Registration Number
- NCT02689141
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 48
- Registration Number
- NCT02445131
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 66
- Registration Number
- NCT02401503
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 66
- Registration Number
- NCT02345863
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 22
- Registration Number
- NCT01558167
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 89
- Registration Number
- NCT01556776
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, Germany
🇩🇪German CLL Study Group, Cologne, Germany
Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 16
- Registration Number
- NCT01186640
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, Germany
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 564
- Registration Number
- NCT00769522
- Locations
- 🇩🇪
Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 13
- Registration Number
- NCT00634881
- Locations
- 🇩🇪
Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany
🇩🇪Universitatsklinikum Heidelberg, Heidelberg, Germany
🇩🇪Klinikum Barnim GmbH, Werner Forssmann Krankenhaus, Eberswalde, Germany
Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2016-09-26
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 83
- Registration Number
- NCT00416910
© Copyright 2024. All Rights Reserved by MedPath